SCHEMBL753591

SCHEMBL753591

CC(=O)OC(c1ccccc1)c1cnc(Cl)c(Cl)c1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 2/20 0.44
OPRM1 P35372 1/20 0.44
OPRD1 P41143 1/20 0.44
RORC P51449 3/20 0.41
HSD17B10 Q99714 1/20 0.40
ALDH1A1 P00352 2/20 0.40
CYP3A4 P08684 1/20 0.40
S1PR2 O95136 1/20 0.37
S1PR4 O95977 1/20 0.37
S1PR3 Q99500 1/20 0.37
S1PR5 Q9H228 1/20 0.37
ESR1 P03372 1/20 0.37
ESR2 Q92731 1/20 0.37
MAPT P10636 1/20 0.37
L3MBTL1 Q9Y468 1/20 0.37
TDP1 Q9NUW8 1/20 0.36
MEN1 O00255 1/20 0.36
IDO1 P14902 1/20 0.36
TDO2 P48775 1/20 0.36
IDO2 Q6ZQW0 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL751082 0.80 CYP3A4 (0.42) RORCHSD17B10ALDH1A1CYP3A4ESR1
SCHEMBL1202828 0.78 ALDH1A1 (0.58) KMT2AHSD17B10ALDH1A1CYP3A4ESR1
SCHEMBL1548815 0.76 OPRM1 (0.42) KMT2AOPRM1OPRD1RORCALDH1A1
Hydrazine SCHEMBL18138498 0.75 ALDH1A1 (0.55) KMT2AHSD17B10ALDH1A1CYP3A4ESR1
SCHEMBL10627201 0.74 FAAH (0.55) FAAH
SCHEMBL25466151 0.73 ALDH1A1 (0.53) KMT2AHSD17B10ALDH1A1CYP3A4ESR1
SCHEMBL11130696 0.72 ALDH1A1 (0.49) KMT2AHSD17B10ALDH1A1CYP3A4ESR1
SCHEMBL28178916 0.72 SMN1; SMN2 (0.50) ALDH1A1CYP3A4CYP19A1FAAH
SCHEMBL11441568 0.71 BRD4 (0.52) KMT2AMEN1IDO1TDO2
Bromide SCHEMBL10735522 0.71 ALDH1A1 (0.47) KMT2AHSD17B10ALDH1A1CYP3A4ESR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2078015-B1 MODULATORS OF GLUCOCORTICOID RECEPTOR, AP-1 AND/OR NF-KAPPAB ACTIVITY AND USE THEREOF BRISTOL MYERS SQUIBB CO (US) 2012-03-21 EP disclosed